Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes

por Bowering, K., Harvey, J., Kolaczynski, J. W., Snyder, J. W., Bode, B. W.
Publicado 2018

The effect of basal–bolus therapy varies with baseline 1,5‐anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis

por Heller, S., Bowering, K., Raskin, P., Liebl, A., Buchholtz, K., Gorst‐Rasmussen, A., Pieber, T. R.
Publicado 2018